Skip to main content
William Abraham, MD, Cardiology, Columbus, OH

WilliamTAbrahamMDFACP, FACC, FAHA, FESC, FRCPE

Cardiology • Columbus, OH

Heart Failure & Transplantation

Professor of Internal Medicine, Physiology, and Cell Biology; College of Medicine Distinguished Professor; The Ohio State University College of Medicine

Join to view full profile

Dr. Abraham is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Abraham's full profile

Already have an account?

  • Office

    452 W 10th Ave
    Columbus, OH 43210
    Phone+1 614-293-7677
    Fax+1 614-293-1456

Summary

  • William T. Abraham, MD is Professor of Internal Medicine and College of Medicine Distinguished Professor at The Ohio State University. Dr. Abraham earned his medical degree from Harvard Medical School, following which he completed residency in Internal Medicine and fellowships in Cardiovascular Diseases and Advanced Heart Failure/Transplant Cardiology at the University of Colorado. At Ohio State, Dr. Abraham has held several leadership positions including Associate Dean for Clinical and Translational Research and Division Director for Cardiovascular Medicine. Dr. Abraham spends the majority of his clinical time managing heart failure patients. He has been recognized as one of the “Best Doctors in America” for twenty consecutive years and has been ranked among the top 10% of physicians nationally in patient satisfaction. Dr. Abraham has received grants from the National Institutes of Health, including more than $11 million in NIH funding over the past 5 years, and has served as national or international PI and on the Executive or Steering Committees of numerous clinical drug and device trials. He has participated in all regulatory phases of new drug and device development from pre-clinical evaluation to Pre-Market Approval and New Drug Application submission and approval. His work has resulted in approval/adoption of new therapies for heart failure, including beta-blockers, cardiac resynchronization therapy, ultrafiltration, implantable hemodynamic monitors, cardiac contractility modulation, transcatheter mitral valve repair, and baroreflex activation therapy. Dr. Abraham has authored more than 1,500 original papers, abstracts, book chapters, and review articles. He has been named to the Clarivate Analytics Highly Cited Researchers list and as one of The World's Most Influential Scientific Minds. He has received the Distinguished Scientist Award from the American College of Cardiology and the Pioneer Award from the Heart Failure Society of America.

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Cardiovascular Disease, 1990 - 1993
  • University of Colorado
    University of ColoradoResidency, Internal Medicine, 1986 - 1990
  • Harvard Medical School
    Harvard Medical SchoolClass of 1986

Certifications & Licensure

  • KY State Medical License
    KY State Medical License 1998 - 2025
  • OH State Medical License
    OH State Medical License 1997 - 2025
  • CO State Medical License
    CO State Medical License 1988 - 2017
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio with Transcatheter Mitral Valve Repair Outcomes  
    Joann Lindenfeld, William T Abraham, Paul A Grayburn, Federico M Asch, Neil J Weissman, Gregg W Stone, JAMA Cardiology
  • The National Coverage Decision for MitraClip in Functional Mitral Regurgitation  
    Satya Shreenivas, William T Abraham, JAMA Cardiology
  • Clinical Research Interatrial Shunting for Heart Failure: Early and Late Results from the First-in-Human Experience with the V-wave System  
    William Abraham, MD, ScienceDirect
  • Join now to see all

Lectures

  • A First-in-Human, Multicenter Open-Label Prospective Study to Evaluate the Safety, Usability, and Performance of the V-Lap System 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
  • Overview Interventional Devices for Heart Failure 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/25/2019
  • Hemodynamic Monitoring Devices in Treating HF: Which Patient and Why? 
    2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
  • Join now to see all

Authored Content

  • Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart FailureApril 2020

Press Mentions

  • The Hole Story: Interatrial Shunt Companies Are—Mostly—Pushing Ahead
    The Hole Story: Interatrial Shunt Companies Are—Mostly—Pushing AheadJune 20th, 2024
  • V-wave Completes Enrollment in the RELIEVE-HF Randomized Double-Blind Controlled Trial of Interatrial Shunting for Heart Failure
    V-wave Completes Enrollment in the RELIEVE-HF Randomized Double-Blind Controlled Trial of Interatrial Shunting for Heart FailureOctober 28th, 2022
  • Smartphone Speech Analysis Detects Worsening Heart Failure Prior to an Event
    Smartphone Speech Analysis Detects Worsening Heart Failure Prior to an EventOctober 4th, 2022
  • Join now to see all

Grant Support

  • Ascending Multidose CI Pharm Study Vpa-985 PTS W/Chronic Congestive Heart FailureNational Center For Research Resources1998–2002
  • Safety And Effectiveness Of IV Administration Of Trk820 In Hyponatremia/Chf PTSNational Center For Research Resources1998–1999
  • Pharmacokinetics Of OPC-41061National Center For Research Resources1998–1999
  • Safety And Tolerance Of Vpa-985 For Patients With Congestive Heart FailureNational Center For Research Resources1997–1999
  • Natriuretic Peptides In Congestive Heart FailureNational Center For Research Resources1995–1996
  • Increased Cardiac Output On ANP Resistance In Cardiac FailureNational Center For Research Resources1994–1995
  • Hemodynamic And Hormonal Changes Of Early Normal Human PregnancyNational Center For Research Resources1991–1992
  • Role Of Hormones In NA Retention Of Patients With Congestive Heart FailureNational Center For Research Resources1989

Professional Memberships

Dr. William Abraham, Dr. William Abraham, MD, Dr. W Abraham, Dr. William T Abraham